A post-marketing active surveillance study to evaluate the risk of Guillain-Barré syndrome, acute disseminated encephalomyelitis, and atrial fibrillation in adults 50 years and older vaccinated with GSK’s Arexvy vaccine in the United States (220149) First published 06/03/2025 Last updated 05/09/2025 EU PAS number:EUPAS1000000486 Study Ongoing